Wikidata

(Q63832014)

English

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

clinical trial

In more languages

Statements

short name
REMAIN (English)
0 references
title
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (English)
0 references
medical condition
multiple sclerosis
0 references
sclerosis
0 references
start time
December 2005
0 references
end time
December 2009
0 references
number of participants
30
0 references
minimum age
18 year
0 references
maximum age
60 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63832014&oldid=1857446588"